Get notified when LFST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (worsened) — The same material weaknesses remain unremediated, and the current quarter's remediation actions are limited to access management, suggesting slower progress than the prior year's broader set of completed controls.
NASDAQ: LFST LifeStance Health Group, Inc. 10-Q

LifeStance swings to profit with revenue up to $435.4M; buyback nearly exhausted

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

  • high

    Revenue rose 26.1% to $435.4M, driven by an 11% larger clinician base and 18-19% more patient visits.

    MD&A: Revenue verify on EDGAR →
  • high

    Operating income swung from a loss; net income reached $23.6M versus a loss.

    MD&A: Results verify on EDGAR →
  • high

    New buyback program is 97.6% used, with only remaining as of June 30, 2026.

    MD&A: Buyback verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (DBI 10-Q) is open in full — no account needed.

Partner

Trade LFST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 14, 2026 · How we verify